Cefamandole clinical pharmacology

Cefamandole

MANDOL® FDA Package Insert
Description
Clinical Pharmacology
Microbiology
Indications and Usage
Contraindications
Warnings and Precautions
Adverse Reactions
Drug Interactions
Overdosage
Dosage and Administration
How Supplied

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

## Clinical Pharmacology

[edit | edit source]

After intramuscular administration of a 500-mg dose of cefamandol (cefamandole) to normal volunteers, the mean peak serum concentration was 13 µg/mL. After a 1-g dose, the mean peak concentration was 25 µg/mL. These peaks occurred at 30 to 120 minutes. Following intravenous doses of 1, 2, and 3 g, serum concentrations were 139, 240, and 533 mcg/mL respectively at 10 minutes. These concentrations declined to 0.8, 2.2, and 2.9 mcg/mL at 4 hours. Intravenous administration of 4-g doses every 6 hours produced no evidence of accumulation in the serum. The half-life after an intravenous dose is 32 minutes; after intramuscular administration, the half-life is 60 minutes.

Sixty-five percent to 85% of cefamandol (cefamandole) is excreted by the kidneys over an 8-hour period, resulting in high urinary concentrations. Following intramuscular doses of 500 mg and 1 g, urinary concentrations averaged 254 and 1,357 mcg/mL respectively. Intravenous doses of 1 and 2 g produced urinary levels averaging 750 and 1,380 mcg/mL respectively. Probenecid slows tubular excretion and doubles the peak serum level and the duration of measurable serum concentrations.

The antibiotic reaches therapeutic levels in pleural and joint fluids and in bile and bone.[1]

## References

[edit | edit source]

1. ↑ "http://www.rxlist.com/mandol-drug.htm". External link in `|title=` (help)

Adapted from the FDA Package Insert.